FOLFOX

Overview

FOLFOX is a combination chemotherapy regimen widely used in the treatment of colorectal cancer and, increasingly, other gastrointestinal malignancies. The name is an acronym derived from its constituent agents: FOLinic acid (leucovorin), Fluorouracil (5-FU), and OXaliplatin. The regimen works through complementary cytotoxic mechanisms: fluorouracil inhibits thymidylate synthase, thereby blocking DNA synthesis in rapidly dividing tumor cells, while leucovorin enhances fluorouracil's binding to its target enzyme, and oxaliplatin forms platinum-DNA adducts that induce apoptosis. The most commonly used formulation, mFOLFOX6 (modified FOLFOX6), involves a simplified dosing schedule of oxaliplatin and leucovorin administered intravenously on day one, followed by a 46-hour continuous infusion of fluorouracil, repeated every two weeks.

Since its clinical introduction, FOLFOX has become a foundational backbone for both adjuvant and first-line metastatic colorectal cancer treatment, and its utility continues to be explored across an expanding range of oncologic contexts. Its compatibility with targeted agents and immune checkpoint inhibitors has made it a versatile platform for combination strategies, while ongoing research continues to probe mechanisms of resistance and optimize patient selection.

Recent Publications Summary

Recent publications have examined FOLFOX across several gastrointestinal malignancies and treatment settings, most often as part of combination regimens or perioperative therapy. In unresectable hepatocellular carcinoma, a prospective phase 2 trial evaluated hepatic arterial infusion chemotherapy with FOLFOX combined with lenvatinib and the PD-L1 inhibitor durvalumab as initial treatment. Among 40 enrolled patients, the regimen produced a median progression-free survival of 15.8 months, a 6-month PFS rate of 77.5%, 1- and 2-year overall survival rates of 97.5% and 94.0%, and an objective response rate of 75.0%, with a disease control rate of 95.0% 42135293May. In stage III mismatch repair-deficient colon cancer, a phase 3 trial tested adjuvant atezolizumab plus mFOLFOX6 versus mFOLFOX6 alone after resection; at a median follow-up of 40.9 months, the 3-year disease-free survival was 86.3% in the combination arm, with overall survival and adverse-event outcomes also assessed 41880612Mar.

FOLFOX has also been studied in colorectal cancer in the perioperative and first-line settings. Long-term follow-up from JCOG0603 showed that adjuvant mFOLFOX6 after hepatectomy for colorectal liver-only metastasis improved disease-free survival in the original trial, but did not demonstrate an overall survival advantage at extended follow-up; 5-year and 7-year overall survival were numerically lower in the mFOLFOX6 arm than in the hepatectomy-alone arm 41564372Jan. In older or frail patients with metastatic colorectal cancer, the randomized phase 2 AIO/IKF ELDERLY trial compared aflibercept plus 5-FU with FOLFOX as first-line treatment, reflecting ongoing efforts to adapt FOLFOX-based therapy to patients not eligible for full-dose combination regimens 41905242Mar. A separate cost-effectiveness analysis in China assessed encorafenib plus cetuximab with or without mFOLFOX6 for untreated BRAF V600E-mutant metastatic colorectal cancer and found that adding mFOLFOX6 did not meet the willingness-to-pay threshold at current prices 42185244May.

Outside colorectal cancer, FOLFOX-based treatment has been reported in gastric cancer and explored in supportive-care and predictive contexts. A case report described an initially unresectable CLDN18.2-positive advanced gastric cancer treated with first-line mFOLFOX6 plus zolbetuximab, followed by conversion surgery and pathological complete response after six cycles 42501157Jul. In gastrointestinal cancer patients receiving adjuvant mFOLFOX6, a prospective observational study compared home-based port infusion with hospital-based peripheral infusion and evaluated anxiety, quality of life, toxicities, and emergency visits over 6 and 12 cycles 42174259May. In pancreatic ductal adenocarcinoma, a ratiometric fluorescent sensor study found that CES2 activity correlated with FOLFIRINOX sensitivity, while such correlations were not observed with FOLFOX, underscoring regimen-specific predictive biology rather than direct evidence of FOLFOX efficacy in that model 42043185Apr.

What Changes, What Holds

1. FOLFOX is now being used as a platform for intensified multimodal therapy in liver-confined and biomarker-defined gastrointestinal cancer, not just as a standard cytotoxic backbone
NEW DIRECTION Hepatic arterial infusion plus FOLFOX with targeted and immune agents in unresectable hepatocellular carcinoma, and adjuvant atezolizumab with mFOLFOX6 in mismatch repair-deficient stage III colon cancer, extend the regimen into settings where the Overview already allows combination use but does not yet specify these newer pairings. The main implication is that FOLFOX remains a flexible scaffold, while the new data mainly refine where and with whom it may be paired 42135293May41880612Mar.

2. Extended follow-up and comparator data temper confidence that more FOLFOX is always better in colorectal cancer
REINFORCES Long-term results after hepatectomy for colorectal liver metastases weaken any assumption that adjuvant mFOLFOX6 necessarily translates into durable survival gain, even when earlier disease-free survival looked favorable. The frail-older-patient comparison also fits the baseline’s theme of adapting FOLFOX-based therapy to less fit populations, but it does not establish a new role for the regimen. Together these findings support a more cautious, context-dependent view of benefit 41564372Jan41905242Mar.

3. FOLFOX is expanding into perioperative gastric cancer care and into practical questions about how infusion delivery affects patient experience
NEW DIRECTION The gastric cancer case shows the regimen being used as part of a conversion strategy with curative intent, which is outside the Overview’s colorectal-centered framing and broad gastrointestinal use. The infusion study does not change efficacy expectations, but it adds a supportive-care dimension by asking how treatment delivery influences anxiety, quality of life, and acute care use. The pancreatic sensor work is only indirect and does not alter FOLFOX’s known antitumor mechanism 42501157Jul42174259May.

Overview update candidates: FOLFOX-based conversion therapy in advanced gastric cancer; the lack of clear overall-survival benefit for adjuvant mFOLFOX6 after hepatectomy for colorectal liver metastases; practical infusion-delivery effects on patient experience.